ArticleJournal of clinical microbiology2012
Phylogenetic distribution of CTX-M- and non-extended-spectrum-β-lactamase-producing Escherichia coli isolates: group B2 isolates, except clone ST131, rarely produce CTX-M enzymes.
Article in Journal of clinical microbiology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 2 syntheses or guidelines pooled it, 63 citations in OpenAlex.
- Global Extraintestinal Pathogenic Escherichia coli (ExPEC) Lineages.Clinical microbiology reviews · 2019Pooled it
- Epidemic potential of Escherichia coli ST131 and Klebsiella pneumoniae ST258: a systematic review and meta-analysis.BMJ open · 2016Pooled it
- Changing paradigm of antibiotic resistance amongst Escherichia coli isolates in Indian pediatric population.PloS one · 2019Trial
- Molecular and Microbiological Characteristics of UropathogenicAnnals of laboratory medicine · 2026Article
- Whole-Genome Analysis ofAntibiotics (Basel, Switzerland) · 2025Article
- A First Report on Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Genotypic Characteristics and Antimicrobial Resistance ofAntibiotics (Basel, Switzerland) · 2023Article
- The impact of the ST131 clone on recurrent ESBL-producing E. coli urinary tract infection: a prospective comparative study.Scientific reports · 2022Article
- Distinguishing Pathovars from Nonpathovars: Escherichia coli.Microbiology spectrum · 2020Review
- Success of Escherichia coli O25b:H4 Sequence Type 131 Clade C Associated with a Decrease in Virulence.Infection and immunity · 2020Article
- Clonal Structure, Virulence Factor-encoding Genes and Antibiotic Resistance ofAntibiotics (Basel, Switzerland) · 2020Article
- High Prevalence of ST131 Subclades C2-Frontiers in cellular and infection microbiology · 2020Article
- Article
- Population Structure and Antimicrobial Resistance of Canine Uropathogenic Escherichia coli.Journal of clinical microbiology · 2018Article
- Increase in antimicrobial resistance and emergence of major international high-risk clonal lineages in dogs and cats with urinary tract infection: 16 year retrospective study.The Journal of antimicrobial chemotherapy · 2018Article
- DNA Damage Repair and Drug Efflux as Potential Targets for Reversing Low or Intermediate Ciprofloxacin Resistance inFrontiers in microbiology · 2018Article
- Clonal Diversity of ESBL-Producing Escherichia coli Isolated from Environmental, Human and Food Samples.International journal of environmental research and public health · 2017Article
- Modulation of Membrane Influx and Efflux in Escherichia coli Sequence Type 131 Has an Impact on Bacterial Motility, Biofilm Formation, and Virulence in a Caenorhabditis elegans Model.Antimicrobial agents and chemotherapy · 2016Article
- Emergence of Antimicrobial-Resistant Escherichia coli of Animal Origin Spreading in Humans.Molecular biology and evolution · 2016Article
- Evolutionary History of the Global Emergence of the Escherichia coli Epidemic Clone ST131.mBio · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli is the species most frequently associated with clinical infections by extended-spectrum-β-lactamase (ESBL)-producing isolates, with the CTX-M ESBL enzymes being predominant and found in genetically diverse E. coli isolates. The main objective of this study was to compare, on the basis of a case-control design, the phylogenetic diversity of 152 CTX-M-producing and 152 non-ESBL-producing clinical E. coli isolates. Multilocus sequence typing revealed that even though CTX-M enzymes were largely disseminated across the diversity of E. coli isolates, phylogenetic group B2 showed a particularly heterogeneous situation. First, clone ST131 of group B2 was strongly associated with CTX-M production (55 [79%] of 70 isolates), with CTX-M-15 being predominant. Second, the remaining members of group B2 were significantly less frequently associated with CTX-M production (9 [12%] of 75) than E. coli phylogenetic groups A, B1, and D (88 [55%] of 159). CTX-M-producing ST131 E. coli isolates were significantly more frequent in patients hospitalized in geriatric wards or long-term care facilities. Besides, the non-ESBL ST131 isolates significantly more frequently showed resistance to penicillins than the non-ESBL, non-ST131 isolates did. In conclusion, the present study emphasizes the particular antimicrobial resistance and epidemiologic characteristics of clone ST131 within group B2, which could result from the higher antibiotic exposure of this clone, as it is the predominant clone of group B2 carried in the human gut.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.